What Switzerland adds to a CE file

Updated on November 15, 2026

In brief

For the 8 classes of medical devices and IVDs that have both an EU pathway and an EU + Switzerland pathway, the second adds 3 to 17 steps to the first. Each addition is listed below, under the phase where it sits, with its estimated duration and, when an article is its basis, its reference in Swiss law.

The gap, class by class

Class A IVD: Switzerland adds 3 steps

Plus 1 new phase.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 44 para. 1 IvDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 48 IvDO

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)

Also required in Switzerland, with no step in this pathway

For this class, Swiss law also provides for the following; the EU + Switzerland pathway does not carry it as a step yet, so the computed gap does not count it.

  • Switzerland — check the appointment of the authorised representativeManufacturers established in the EU or EEA had deadlines, staggered by class, for appointing the authorised representative. (Art. 86 IvDO)Deadlines for in vitro diagnostic devices placed on the market as from May 26, 2022, all past: class D on December 31, 2022; classes B and C on March 31, 2023; class A on July 31, 2023. (Art. 86 IvDO)
  • Switzerland — languages of the product informationDevice information is written in the three official languages; standardised symbols are allowed. (Art. 15 para. 2 IvDO; Art. 45 para. 3 let. c TPA (in French))For self-testing and near-patient testing in vitro diagnostic devices, the information must be easy to understand and written in the three official languages. (Art. 15 para. 8 IvDO)
  • Switzerland — account for discounts and rebatesDiscounts and rebates granted or accepted when buying therapeutic products are shown in vouchers, invoices and accounts, and disclosed to the FOPH on request. (Art. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French))
  • Switzerland — set up internal control arrangementsAnyone manufacturing or distributing the therapeutic products concerned designates a contact person for the FOPH, keeps agreements for 10 years and maintains a list of recipients of permitted benefits. (Art. 11 SR 812.214.31 (in French))
EU roadmapEU + Switzerland roadmap

Class B IVD: Switzerland adds 3 steps

Plus 1 new phase.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 44 para. 1 IvDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 48 IvDO

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)

Also required in Switzerland, with no step in this pathway

For this class, Swiss law also provides for the following; the EU + Switzerland pathway does not carry it as a step yet, so the computed gap does not count it.

  • Switzerland — check the appointment of the authorised representativeManufacturers established in the EU or EEA had deadlines, staggered by class, for appointing the authorised representative. (Art. 86 IvDO)Deadlines for in vitro diagnostic devices placed on the market as from May 26, 2022, all past: class D on December 31, 2022; classes B and C on March 31, 2023; class A on July 31, 2023. (Art. 86 IvDO)
  • Switzerland — languages of the product informationDevice information is written in the three official languages; standardised symbols are allowed. (Art. 15 para. 2 IvDO; Art. 45 para. 3 let. c TPA (in French))For self-testing and near-patient testing in vitro diagnostic devices, the information must be easy to understand and written in the three official languages. (Art. 15 para. 8 IvDO)
  • Switzerland — account for discounts and rebatesDiscounts and rebates granted or accepted when buying therapeutic products are shown in vouchers, invoices and accounts, and disclosed to the FOPH on request. (Art. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French))
  • Switzerland — set up internal control arrangementsAnyone manufacturing or distributing the therapeutic products concerned designates a contact person for the FOPH, keeps agreements for 10 years and maintains a list of recipients of permitted benefits. (Art. 11 SR 812.214.31 (in French))
EU roadmapEU + Switzerland roadmap

Class C IVD: Switzerland adds 3 steps

Plus 1 new phase.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 44 para. 1 IvDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 48 IvDO

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)

Also required in Switzerland, with no step in this pathway

For this class, Swiss law also provides for the following; the EU + Switzerland pathway does not carry it as a step yet, so the computed gap does not count it.

  • Switzerland — check the appointment of the authorised representativeManufacturers established in the EU or EEA had deadlines, staggered by class, for appointing the authorised representative. (Art. 86 IvDO)Deadlines for in vitro diagnostic devices placed on the market as from May 26, 2022, all past: class D on December 31, 2022; classes B and C on March 31, 2023; class A on July 31, 2023. (Art. 86 IvDO)
  • Switzerland — languages of the product informationDevice information is written in the three official languages; standardised symbols are allowed. (Art. 15 para. 2 IvDO; Art. 45 para. 3 let. c TPA (in French))For self-testing and near-patient testing in vitro diagnostic devices, the information must be easy to understand and written in the three official languages. (Art. 15 para. 8 IvDO)
  • Switzerland — account for discounts and rebatesDiscounts and rebates granted or accepted when buying therapeutic products are shown in vouchers, invoices and accounts, and disclosed to the FOPH on request. (Art. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French))
  • Switzerland — set up internal control arrangementsAnyone manufacturing or distributing the therapeutic products concerned designates a contact person for the FOPH, keeps agreements for 10 years and maintains a list of recipients of permitted benefits. (Art. 11 SR 812.214.31 (in French))
EU roadmapEU + Switzerland roadmap

Class D IVD: Switzerland adds 3 steps

Plus 1 new phase.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 44 para. 1 IvDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 48 IvDO

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)

Also required in Switzerland, with no step in this pathway

For this class, Swiss law also provides for the following; the EU + Switzerland pathway does not carry it as a step yet, so the computed gap does not count it.

  • Switzerland — check the appointment of the authorised representativeManufacturers established in the EU or EEA had deadlines, staggered by class, for appointing the authorised representative. (Art. 86 IvDO)Deadlines for in vitro diagnostic devices placed on the market as from May 26, 2022, all past: class D on December 31, 2022; classes B and C on March 31, 2023; class A on July 31, 2023. (Art. 86 IvDO)
  • Switzerland — languages of the product informationDevice information is written in the three official languages; standardised symbols are allowed. (Art. 15 para. 2 IvDO; Art. 45 para. 3 let. c TPA (in French))For self-testing and near-patient testing in vitro diagnostic devices, the information must be easy to understand and written in the three official languages. (Art. 15 para. 8 IvDO)
  • Switzerland — account for discounts and rebatesDiscounts and rebates granted or accepted when buying therapeutic products are shown in vouchers, invoices and accounts, and disclosed to the FOPH on request. (Art. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French))
  • Switzerland — set up internal control arrangementsAnyone manufacturing or distributing the therapeutic products concerned designates a contact person for the FOPH, keeps agreements for 10 years and maintains a list of recipients of permitted benefits. (Art. 11 SR 812.214.31 (in French))
EU roadmapEU + Switzerland roadmap

Class I medical device: Switzerland adds 14 steps

Plus 1 new phase.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 51 para. 1 MedDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 55 MedDO

Post-Market Surveillance (PMS)

Added stepEstimated durationLegal basis
Prepare the PSUR2 dThe safety report is required for classes IIa, IIb and III; class I prepares a post-market surveillance report. (Art. 60 para. 1 MedDO; Art. 59 para. 1 MedDO)

Clinical investigation

Added stepEstimated durationLegal basis
Switzerland — classify the clinical trial category5 dArt. 6 para. 1 CTO-MedD (in French); Art. 6 para. 3 CTO-MedD (in French); Art. 7 CTO-MedD (in French)
Switzerland — dual authorisation, ethics committee then Swissmedic90 dArt. 19 para. 2 CTO-MedD (in French); Art. 12 para. 2 CTO-MedD (in French)
Switzerland — appoint a representative of the sponsor15 dArt. 4 para. 3 CTO-MedD (in French)
Switzerland — guarantee liability and organise consent30 d
Switzerland — adapt the application file20 dArt. 10 para. 1 CTO-MedD (in French); Art. 16 para. 1 CTO-MedD (in French)
Switzerland — substantial modifications38 dArt. 15 para. 3 CTO-MedD (in French); Art. 20 para. 3 CTO-MedD (in French)
Switzerland — safety reporting during the trial10 d
Switzerland — closure, final report and retention365 dArt. 36 para. 1 CTO-MedD (in French); Art. 36 para. 4 CTO-MedD (in French); Art. 37 para. 1 CTO-MedD (in French); Art. 40 para. 1 CTO-MedD (in French)

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — languages of the product information20 dArt. 16 para. 2 MedDO; Art. 45 para. 3 let. c TPA (in French)
Switzerland — check the appointment of the authorised representative10 dArt. 104a MedDO
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)
EU roadmapEU + Switzerland roadmap

Class IIa medical device: Switzerland adds 17 steps

Plus 2 new phases.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 51 para. 1 MedDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 55 MedDO

Integrity and transparency (Switzerland)New phase

Added stepEstimated durationLegal basis
Switzerland — determine whether transparency applies to you10 d
Switzerland — account for discounts and rebates20 dArt. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French)
Switzerland — set up internal control arrangements30 dArt. 11 SR 812.214.31 (in French)
Switzerland — congresses, training and paid services20 dThe integrity thresholds (benefits of modest value, own contribution, meals) implement Art. 55 TPA, whose para. 1 concerns prescription-only medicinal products. (Art. 55 para. 1 TPA (in French); Art. 55 para. 3 TPA (in French))

Clinical investigation

Added stepEstimated durationLegal basis
Switzerland — classify the clinical trial category5 dArt. 6 para. 1 CTO-MedD (in French); Art. 6 para. 3 CTO-MedD (in French); Art. 7 CTO-MedD (in French)
Switzerland — dual authorisation, ethics committee then Swissmedic90 dArt. 19 para. 2 CTO-MedD (in French); Art. 12 para. 2 CTO-MedD (in French)
Switzerland — appoint a representative of the sponsor15 dArt. 4 para. 3 CTO-MedD (in French)
Switzerland — guarantee liability and organise consent30 d
Switzerland — adapt the application file20 dArt. 10 para. 1 CTO-MedD (in French); Art. 16 para. 1 CTO-MedD (in French)
Switzerland — substantial modifications38 dArt. 15 para. 3 CTO-MedD (in French); Art. 20 para. 3 CTO-MedD (in French)
Switzerland — safety reporting during the trial10 d
Switzerland — closure, final report and retention365 dArt. 36 para. 1 CTO-MedD (in French); Art. 36 para. 4 CTO-MedD (in French); Art. 37 para. 1 CTO-MedD (in French); Art. 40 para. 1 CTO-MedD (in French)

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — languages of the product information20 dArt. 16 para. 2 MedDO; Art. 45 para. 3 let. c TPA (in French)
Switzerland — check the appointment of the authorised representative10 dArt. 104a MedDO
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)
EU roadmapEU + Switzerland roadmap

Class IIb medical device: Switzerland adds 17 steps

Plus 2 new phases.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 51 para. 1 MedDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 55 MedDO

Integrity and transparency (Switzerland)New phase

Added stepEstimated durationLegal basis
Switzerland — determine whether transparency applies to you10 d
Switzerland — account for discounts and rebates20 dArt. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French)
Switzerland — set up internal control arrangements30 dArt. 11 SR 812.214.31 (in French)
Switzerland — congresses, training and paid services20 dThe integrity thresholds (benefits of modest value, own contribution, meals) implement Art. 55 TPA, whose para. 1 concerns prescription-only medicinal products. (Art. 55 para. 1 TPA (in French); Art. 55 para. 3 TPA (in French))

Clinical investigation

Added stepEstimated durationLegal basis
Switzerland — classify the clinical trial category5 dArt. 6 para. 1 CTO-MedD (in French); Art. 6 para. 3 CTO-MedD (in French); Art. 7 CTO-MedD (in French)
Switzerland — dual authorisation, ethics committee then Swissmedic90 dArt. 19 para. 2 CTO-MedD (in French); Art. 12 para. 2 CTO-MedD (in French)
Switzerland — appoint a representative of the sponsor15 dArt. 4 para. 3 CTO-MedD (in French)
Switzerland — guarantee liability and organise consent30 d
Switzerland — adapt the application file20 dArt. 10 para. 1 CTO-MedD (in French); Art. 16 para. 1 CTO-MedD (in French)
Switzerland — substantial modifications38 dArt. 15 para. 3 CTO-MedD (in French); Art. 20 para. 3 CTO-MedD (in French)
Switzerland — safety reporting during the trial10 d
Switzerland — closure, final report and retention365 dArt. 36 para. 1 CTO-MedD (in French); Art. 36 para. 4 CTO-MedD (in French); Art. 37 para. 1 CTO-MedD (in French); Art. 40 para. 1 CTO-MedD (in French)

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — languages of the product information20 dArt. 16 para. 2 MedDO; Art. 45 para. 3 let. c TPA (in French)
Switzerland — check the appointment of the authorised representative10 dArt. 104a MedDO
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)
EU roadmapEU + Switzerland roadmap

Class III medical device: Switzerland adds 17 steps

Plus 2 new phases.

Swiss formalitiesNew phase · 14 d

Added stepEstimated durationLegal basis
Appoint a Swiss authorised representative14 dArt. 51 para. 1 MedDO
Register the economic operator with Swissmedic14 dSwissmedic, swissdamed: device registration (in French); Art. 55 MedDO

Integrity and transparency (Switzerland)New phase

Added stepEstimated durationLegal basis
Switzerland — determine whether transparency applies to you10 d
Switzerland — account for discounts and rebates20 dArt. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French)
Switzerland — set up internal control arrangements30 dArt. 11 SR 812.214.31 (in French)
Switzerland — congresses, training and paid services20 dThe integrity thresholds (benefits of modest value, own contribution, meals) implement Art. 55 TPA, whose para. 1 concerns prescription-only medicinal products. (Art. 55 para. 1 TPA (in French); Art. 55 para. 3 TPA (in French))

Clinical investigation

Added stepEstimated durationLegal basis
Switzerland — classify the clinical trial category5 dArt. 6 para. 1 CTO-MedD (in French); Art. 6 para. 3 CTO-MedD (in French); Art. 7 CTO-MedD (in French)
Switzerland — dual authorisation, ethics committee then Swissmedic90 dArt. 19 para. 2 CTO-MedD (in French); Art. 12 para. 2 CTO-MedD (in French)
Switzerland — appoint a representative of the sponsor15 dArt. 4 para. 3 CTO-MedD (in French)
Switzerland — guarantee liability and organise consent30 d
Switzerland — adapt the application file20 dArt. 10 para. 1 CTO-MedD (in French); Art. 16 para. 1 CTO-MedD (in French)
Switzerland — substantial modifications38 dArt. 15 para. 3 CTO-MedD (in French); Art. 20 para. 3 CTO-MedD (in French)
Switzerland — safety reporting during the trial10 d
Switzerland — closure, final report and retention365 dArt. 36 para. 1 CTO-MedD (in French); Art. 36 para. 4 CTO-MedD (in French); Art. 37 para. 1 CTO-MedD (in French); Art. 40 para. 1 CTO-MedD (in French)

Ongoing obligations and compliance checks

Added stepEstimated durationLegal basis
Switzerland — languages of the product information20 dArt. 16 para. 2 MedDO; Art. 45 para. 3 let. c TPA (in French)
Switzerland — check the appointment of the authorised representative10 dArt. 104a MedDO
Switzerland — obtain an export certificate from Swissmedic30 dArt. 50 para. 2 TPA (in French); Annex 2 no. 4 SR 812.214.5 (in French)
EU roadmapEU + Switzerland roadmap

Legal basis of each addition

For each added step that an article provides for, the rule and its source. A step missing from this list has no verified fact in Normiq's base yet.

Appoint a Swiss authorised representative
A manufacturer without a registered office in Switzerland may place its devices on the market only after appointing, by written mandate, an authorised representative established in Switzerland. (Art. 51 para. 1 MedDO; Art. 44 para. 1 IvDO)
Register the economic operator with Swissmedic
Registration of economic operators (CHRN) has been mandatory in Switzerland since November 26, 2021; it has been done in swissdamed since August 2024. (Swissmedic, swissdamed: device registration (in French))
The manufacturer or its authorised representative, and the importer, register with Swissmedic before first placing on the market; Swissmedic assigns the CHRN. (Art. 55 MedDO; Art. 48 IvDO)
Switzerland — obtain an export certificate from Swissmedic
On request, Swissmedic may issue the export certificates required by another state to a manufacturer or authorised representative established in Switzerland. (Art. 50 para. 2 TPA (in French))
An export certificate for a medical device costs CHF 200. (Annex 2 no. 4 SR 812.214.5 (in French))
Switzerland — check the appointment of the authorised representative
Manufacturers established in the EU or EEA had deadlines, staggered by class, for appointing the authorised representative. (Art. 104a MedDO; Art. 86 IvDO)
Deadlines for medical devices, all past: class III, implantable class IIb and active implantable medical devices on December 31, 2021; non-implantable class IIb and class IIa on March 31, 2022; class I, systems and procedure packs on July 31, 2022. (Art. 104a MedDO)
Deadlines for in vitro diagnostic devices placed on the market as from May 26, 2022, all past: class D on December 31, 2022; classes B and C on March 31, 2023; class A on July 31, 2023. (Art. 86 IvDO)
Switzerland — languages of the product information
Device information is written in the three official languages; standardised symbols are allowed. (Art. 16 para. 2 MedDO; Art. 15 para. 2 IvDO; Art. 45 para. 3 let. c TPA (in French))
For self-testing and near-patient testing in vitro diagnostic devices, the information must be easy to understand and written in the three official languages. (Art. 15 para. 8 IvDO)
Switzerland — account for discounts and rebates
Discounts and rebates granted or accepted when buying therapeutic products are shown in vouchers, invoices and accounts, and disclosed to the FOPH on request. (Art. 56 para. 1 TPA (in French); Art. 10 para. 1 SR 812.214.31 (in French))
Switzerland — set up internal control arrangements
Anyone manufacturing or distributing the therapeutic products concerned designates a contact person for the FOPH, keeps agreements for 10 years and maintains a list of recipients of permitted benefits. (Art. 11 SR 812.214.31 (in French))
Prepare the PSUR
The safety report is required for classes IIa, IIb and III; class I prepares a post-market surveillance report. (Art. 60 para. 1 MedDO; Art. 59 para. 1 MedDO)
Switzerland — classify the clinical trial category
A trial is category A if the device bears a conformity marking, is used according to its instructions for use and is not prohibited in Switzerland; otherwise it is category C. Category A does not require Swissmedic authorisation. (Art. 6 para. 1 CTO-MedD (in French); Art. 6 para. 3 CTO-MedD (in French); Art. 7 CTO-MedD (in French))
Switzerland — dual authorisation, ethics committee then Swissmedic
The ethics committee decides within 40 days; Swissmedic within 45 days, and only after the ethics committee has authorised the trial. (Art. 19 para. 2 CTO-MedD (in French); Art. 12 para. 2 CTO-MedD (in French))
Switzerland — appoint a representative of the sponsor
A sponsor with no registered office or establishment in Switzerland designates, as its address for service, a representative with a registered office or establishment in Switzerland. (Art. 4 para. 3 CTO-MedD (in French))
Switzerland — adapt the application file
The application dossier follows Annex 1 of the CTO-MedD, for the ethics committee and for Swissmedic alike. (Art. 10 para. 1 CTO-MedD (in French); Art. 16 para. 1 CTO-MedD (in French))
Switzerland — substantial modifications
Substantial modifications: ethics committee decision within 30 days, Swissmedic within 38 days, extendable by 7 days. (Art. 15 para. 3 CTO-MedD (in French); Art. 20 para. 3 CTO-MedD (in French))
Switzerland — closure, final report and retention
End of the trial notified within 15 days, termination for safety reasons within 24 hours; final report within 1 year, or 3 months after early termination; data kept for at least 10 years, 15 years for implantable devices. (Art. 36 para. 1 CTO-MedD (in French); Art. 36 para. 4 CTO-MedD (in French); Art. 37 para. 1 CTO-MedD (in French); Art. 40 para. 1 CTO-MedD (in French))
Switzerland — congresses, training and paid services
The integrity thresholds (benefits of modest value, own contribution, meals) implement Art. 55 TPA, whose para. 1 concerns prescription-only medicinal products. (Art. 55 para. 1 TPA (in French); Art. 55 para. 3 TPA (in French))

Further reading

Method

A step or phase counts as an addition when its reference appears in the EU + Switzerland pathway and nowhere in the EU pathway of the same class, neither as a phase nor as a step. The computation only goes one way: it says what Switzerland adds, not what the EU + Switzerland pathway takes over from the EU pathway. Medicinal products have no EU pathway and are therefore not included. Data: published structure of the roadmaps, generated on November 17, 2026.